Neuland Laboratories Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹24,808 Cr
- Book Value
- ₹1,461
- Stock P/E
- 68.7
- Dividend Yield
- 0.18%
- ROE
- 21.3%
- ROCE
- 26.5%
- PEG Ratio
- 1.78
- EV/EBITDA
- 41.1
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Neuland Laboratories share price today
Neuland Laboratories (NSE: NEULANDLAB) climbed pharma’s value chain the patient way: three decades of API manufacturing discipline, then a decisive pivot into CMS — custom manufacturing for innovators — where it now makes complex molecules (and increasingly peptides, the chemistry behind the GLP-1 era) for global drug companies from clinical phases through commercial launch. When an innovator’s molecule wins, Neuland’s contracted volumes win with it.
The P&L shows the mix shifting: 28.7% operating margins (unrecognisable from its generic-API past), 38.5% five-year profit CAGR, ROCE past 26%. At 68.7×, our universe keeps it on watch, flags attached: a 2.29% promoter pledge and client concentration inherent to CMS.
The innovator’s contract shop
CMS economics are event-driven annuities: development revenue during trials, then scale-up, then years of commercial supply if the drug succeeds — with switching locked by regulatory filings that name Neuland’s plants. The peptide capability is the timely kicker: GLP-1-class molecules need exactly this chemistry at exactly this scale-up quality, and qualified capacity is globally scarce. The legacy API book (deuterated compounds, niche generics) funds the pipeline while CMS compounds.
Watch-items: CMS client concentration (a few molecules can dominate), the flagged 2.29% promoter pledge, commercial-launch timing of pipeline molecules (binary quarters), and capacity-expansion execution.
The numbers
From our research universe snapshot (5 Aug 2026):
| Metric | Value |
|---|---|
| Market cap | ₹24,808 Cr |
| P/E (TTM) | 68.7 |
| EV/EBITDA | 41.1 |
| Operating margin | 28.7% |
| ROE / ROCE | 21.3% / 26.5% |
| Debt to equity | 0.16 |
| Sales CAGR (5y) | 16.6% |
| Profit CAGR (5y) | 38.5% |
| Promoter holding | 32.6% (2.29% pledged) |
| EPS (TTM) | ₹280.5 |
Neuland Laboratories share price target 2026 to 2030
EPS base ₹280.5 (TTM). Bear: a key molecule disappoints, growth normalises — 10% growth, multiple at 35×. Base: CMS pipeline converts steadily — 18% growth at 50×. Bull: peptide era scales through Neuland — 25% growth at 65×.
| Year | Bear (35×, +10%) | Base (50×, +18%) | Bull (65×, +25%) |
|---|---|---|---|
| 2026 | ₹10,800 | ₹16,550 | ₹22,790 |
| 2027 | ₹11,880 | ₹19,530 | ₹28,490 |
| 2028 | ₹13,065 | ₹23,045 | ₹35,610 |
| 2029 | ₹14,375 | ₹27,190 | ₹44,515 |
| 2030 | ₹15,810 | ₹32,085 | ₹55,640 |
From ₹19,273, the base case is ≈ +66% over four and a half years; the bear is −18%. CDMO stories are molecule-event driven — lumpy up and down — which is why the range below insists on buying the platform, never the quarter.
Reasons to own Neuland (at the right price)
- CMS annuities: regulatory filings lock its plants into innovators’ supply chains.
- Peptide capability lands precisely on the GLP-1 decade’s scarcest input.
- Margin transformation (28.7% OPM) evidences the mix shift is real.
- 38.5% five-year profit CAGR with ROCE climbing past 26%.
- Three decades of FDA-inspected manufacturing credibility.
The risks: client/molecule concentration makes single events material, the promoter pledge (2.29%) is small but flagged for a reason, and 69× prices continued conversion success.
Should you buy at the current price?
The live buy range below is for members — platform price, not quarter price.
FAQ
What is the Neuland Laboratories share price target for 2030? Base case ≈ ₹32,085 (50× on 18% compounded growth), bear ≈ ₹15,810, bull ≈ ₹55,640. Arithmetic above.
What is the CMS business? Custom Manufacturing Solutions — making innovators’ proprietary molecules under contract from clinical through commercial phases. Revenue scales with the client drug’s success and stays locked by regulatory filings.
Why do peptides matter now? GLP-1 obesity/diabetes drugs are peptide-based and supply-constrained globally. Qualified peptide API capacity — Neuland’s build-out — is among pharma’s scarcest assets this decade.
When are Neuland’s next results? Track the exact date on our results calendar.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.